anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Transgenic plants stably overexpressing ScOPR1 gene enhanced disease resistance by increasing the accumulation of JA, SA, and GST, as well as up-regulating the expression of genes related to signaling pathways. 12-Oxo-phytodienoate reductase (OPR) is an oxidoreductase that depends on flavin mononucleotide (FMN) and catalyzes the conversion of 12-oxophytodienoate (12-OPDA) into jasmonic acid (JA). It plays a key role in plant growth and development, and resistance to adverse stresses. In our previous study, we have obtained an OPR gene (ScOPR1, GenBank Accession Number: MG755745) from sugarcane. This gene showed positive responses to methyl jasmonate (MeJA), salicylic acid (SA), abscisic acid (ABA), and Sporisorium scitamineum, suggesting its potential for pathogen resistance. Here, in our study, we observed that Nicotiana benthamiana leaves transiently overexpressing ScOPR1 exhibited weaker disease symptoms, darker 3,3-diaminobenzidine (DAB) staining, higher accumulation of reactive oxygen species (ROS), and higher expression of hypersensitive response (HR) and SA pathway-related genes after inoculation with Ralstonia solanacearum and Fusarium solanacearum var. coeruleum. Furthermore, the transgenic N. benthamiana plants stably overexpressing the ScOPR1 gene showed enhanced resistance to pathogen infection by increasing the accumulation of JA, SA, and glutathione S-transferase (GST), as well as up-regulating genes related to HR, JA, SA, and ROS signaling pathways. Transcriptome analysis revealed that the specific differentially expressed genes (DEGs) in ScOPR1-OE were significantly enriched in hormone transduction signaling and plant-pathogen interaction pathways. Finally, a functional mechanism model of the ScOPR1 gene in response to pathogen infection was depicted. This study provides insights into the molecular mechanism of ScOPR1 and presents compelling evidence supporting its positive involvement in enhancing plant disease resistance.
Magnesium intoxication is manifested by a sharp drop in blood pressure and respiratory paralysis. Disappearance of the patellar reflex is a useful clinical sign to detect the onset of magnesium intoxication. In the event of overdosage, artificial ventilation must be provided until a calcium salt can be injected IV to antagonize the effects of magnesium.

For Treatment of Overdose 

Artificial respiration is often required. Intravenous calcium, 10 to 20 mL of a 5% solution (diluted if desirable) with isotonic sodium chloride for injection) is used to counteract effects of hypermagnesemia. Subcutaneous physostigmine, 0.5 to 1 mg may be helpful. 

Hypermagnesemia in the newborn may require resuscitation and assisted ventilation via endotracheal intubation or intermittent positive pressure ventilation as well as IV calcium.
An oral delivery system for Class II drugs that have low oral bioavailability due to their insolubility in water and slow dissolution kinetics and method for making such a drug delivery system are disclosed herein. The formulation may be a controlled release or immediate release formulation. The immediate release formulation contains a Class II drug, together with a hydrophobic polymer, preferably a bioadhesive polymer. In one embodiment, the drug and polymer are co-dissolved in a common solvent. The solution is formed into small solid particles by any convenient method, particularly by spray drying.  The resulting particles contain drug dispersed as small particles in a polymeric matrix. The particles are stable against aggregation, and can be put into capsules or tableted for administration. The controlled release formulations contain a BCS Class II drug and a bioadhesive polymer. The controlled release formulations may be in the form of a tablet, capsules, mini-tab, microparticulate, or osmotic pump. Enhancement of oral uptake of the drug from use of bioadhesive polymers occurs through (1) increased dissolution kinetics due to stable micronization of the drug, (2) rapid release of the drug from the polymer in the GI tract; and (3) prolonged GI transit due to bioadhesive properties of the polymers. The combination of these effects allows the preparation of a compact, stable dosage form suitable for oral administration of many class II drugs.
The invention relates to a novel strain of lactic bacteria comprising at least one sequence selected from a group consisting of nucleotide sequences SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8 and to a method for the production of said strains. The invention also relates to the sequences SEQ ID Nos. 1-8 and to a nucleic acid, vectors and plasmids comprising said sequences. The invention further relates to food products, especially milk products containing said strains.
The present invention relates to a composition for preventing or treating a metabolic disease, a liver disease, or a muscle disease, the composition comprising Leuconostoc sp. bacteria-derived vesicles. The inventors of the present invention confirmed that, when Leuconostoc sp. bacteria-derived vesicles were administered to an animal model with a high-fat diet-induced metabolic disease, the vesicles efficiently suppressed the high-fat diet-induced metabolic disease, and when Leuconostoc sp. bacteria-derived vesicles were administered to an animal model with a liver disease induced by a choline-deficient, L-amino acid-defined high-fat diet, the vesicles efficiently suppressed the liver disease, and when Leuconostoc sp. bacteria-derived vesicles were administered to muscle cells, the vesicles increased AMPK signaling, which inhibits metabolic stress-induced cell death. Therefore, the Leuconostoc sp. bacteria-derived vesicles according to the present invention can be effectively used in the development of medicines, health functional foods or the like for preventing, ameliorating the symptoms of or treating a metabolic disease, a liver disease, a muscle disease, or the like.
BACKGROUND Heart failure and end-stage renal disease often coexist, and management of heart failure can be challenging in patients during hemodialysis. Sacubitril-valsartan (SV) is the first drug to receive regulatory approval for use in patients with chronic heart failure with reduced ejection fraction (HFrEF) and New York Heart Association (NYHA) classification II, III, or IV. This study aimed to evaluate the efficacy and safety of SV for use in chronic heart failure patients on maintenance hemodialysis (MHD). MATERIAL AND METHODS From September 2021 to October 2022, 28 patients on MHD with chronic heart failure at the hemodialysis center of Shaanxi Second Provincial People's Hospital were regularly followed. During the 12-week follow-up period, all patients were administered SV at doses of 100-400 mg per day. Biochemical indicators, echocardiographic parameters, life quality scores, and adverse events were evaluated. RESULTS We enrolled 28 patients. Compared with the baseline levels, NYHA class III in these patients treated with SV was significantly decreased from 60.71% to 32.14% (P<0.05), left ventricular ejection fraction (LVEF) was significantly improved from 44.29±8.92% to 53.32±7.88% (P<0.001), the Physical Component Summary (PCS) score was significantly improved from 40.0±6.41 to 56.20±9.86 (P<0.001), and the Mental Component Summary (MCS) score was significantly improved from 39.99±6.14 to 52.59±11.0 (P<0.001). CONCLUSIONS We demonstrated that SV improved NYHA classification and LVEF values of patients on MHD with chronic heart failure and also improved their quality of life.
A method is disclosed for determining result data based upon medical measurement data of an examination object. Within the method, a high-dimensional first parameter space is formed, in which measurement values of the various measurements are represented with the aid of value tuples. The measurement values of the various measurements are assigned to a value tuple based on their spatial arrangement in the examination object and/or on their temporal arrangement relative to one another. In the first parameter space, the value tuples are analyzed, using at least one mapping function to at least one further parameter space including a lower dimension than the first parameter space, in order to obtain result data. Furthermore, the result data is output, preferably visualized. In addition, a corresponding device for determining result data is described.
Heart transplantation is a lifesaving procedure however, more then 20% of patients do not survive beyond 3 years, being the cardiac allograft afflicted by cardiac allograft vasculopathy (CAV), which results in allograft loss. The purine adenosine 5'-triphosphate (ATP), released during cell damage/inflammation, is sensed by the ionotropic purinergic P2X7 receptor (P2X7R), which is expressed primarily, though not exclusively, on lymphocytes, thus regulating T cell activation. Loss-of-function single nucleotide mutations (SNPs) have been detected for P2X7R gene; particularly the Glu496 to Ala 1513A\>C (rs3751143) P2X7R loss-of-function mutation is relatively common (1-3% of individuals are mutated omozygous and 25% are heterozygous). Our central hypothesis is that a loss-of-function P2X7R mutation identifies a group of cardiac transplanted patients at high risk for CAV and cardiac allograft loss because of a compensatory overexpression of P2X1R/P2X4R, which induces a disregulation of T-bet/ROR-g, ultimately leading to the abnormal generation of Th1/Th17 cells. Our primary goal is to define the effect of the P2X7R loss-of-function mutation on clinical end points in the CTOT-05 cohort of cardiac transplant recipients (200 patients) and to explore the effects of the mutation on the immune system. Our preliminary data demonstrated that P2X7R increases during cardiac transplant rejection in vivo in mice and in humans and it is activated by ATP released by cardiac cells, thus triggering activation of Th1/Th17 cells. However, while short-term disruption of the P2X7R pathway prolongs cardiac allograft survival, the genetic deletion of P2X7R accelerates CAV and shortens cardiac allograft survival. This was evident in P2X7R KO-B6 mice and in a group of cardiac transplant recipients bearing the P2X7R loss-of-function mutation. Based on our published results and our novel observations, we have developed the following working hypothesis: P2X7R loss-of-function mutation generates a compensatory overexpression of the other ionotropic purinergic receptors (P2X1/P2X4) with chronic delivery of ATP immunity, hyperactivation T-bet/ROR-g, abnormal generation of Th1/Th17 cells and ultimately leading to accelerated CAV and to cardiac allograft loss. To test this hypothesis, we will follow two main paths: i) we will evaluate in the CTOT-05 cohort of cardiac transplant recipients the effect of the Glu496 to Ala 1513A\>C (rs3751143) P2X7R loss-of-function mutation on clinical end points (development of coronary artery vasculopathy, death, re-transplantation or re-listed for transplantation, any rejection) in the first year post transplant; ii) we will explore in vivo and ex vivo in the CTOT-05 cohort of cardiac transplant recipients the effects of P2X7R loss-of-function mutation on the immune system.
The invention discloses a gene editing system and application thereof in constructing HPS1 gene mutation sea pulvis syndrome model pig nuclear transfer donor cells. The present invention provides SEQ ID NO:16, the HPS1-gRNA1 shown in SEQ ID NO:17 and the NCN protein of HPS1-gRNA4 in the preparation of the kit. The invention also provides a method for preparing recombinant cells: and (3) co-transfecting the HPS1-gRNA1, the HPS1-gRNA4 and the NCN protein into pig cells to obtain recombinant cells. The recombinant cell is a recombinant cell with mutation of HPS1 gene. The kit has the following purposes: preparing recombinant cells; preparing a sea-pup syndrome model pig; preparing a cell model of the Haipu syndrome, a tissue model of the Haipu syndrome or an organ model of the Haipu syndrome. The invention has great application value for research and development of the sea-borne syndrome drug and revealing the pathogenesis of the sea-borne syndrome.
The invention discloses a medicine preparation for preventing and treating bacterial respiratory diseases of livestock and poultry. The medicine preparation is prepared from the following components in parts by weight: 5-15 parts of florfenicol, 4-10 parts of oldenlandia diffusa, 1-4 parts of astragalus membranaceus, 3-6 parts of fructo-oligosaccharide, 20-30 parts of medical stones, 15-25 parts of glucosum anhydricum and 0.1-1 part of tween-80. The invention further discloses a method for preparing the medicine preparation. The components of the medicine preparation are mutually compatible to promote absorption of florfenicol, enhance the effects of the components, especially remarkably reduce two major side effects of florfenicol and perform immunosuppression and inhibit growth of beneficial flora in intestines. Furthermore, the medicine preparation can be used for protecting and promoting growth of normal flora in intestines and enhancing body immunity. The preparation method is simple and convenient, and is easy to popularize and apply.
A system and method for the supply of a medical storage container that has a required inventory of medical articles. An enclosure is used to isolate, scan, and inventory a tray or other container of medical articles. The container and each of the medical articles stored in the container having a wireless identification device. A probe injects activation energy and receives identification data in the enclosure. A program compares the scanned identification of the tray and the inventory of the tray to the required inventory list for the tray and indicates any differences. Extra articles and expired and recalled articles are identified. Text and graphical data displays of inventory are provided. Selectable periods for expiration of medical articles are also provided.
The experience of itch and its associated chronic conditions (i.e., atopic dermatitis) form a significant burden of disease. Knowledge of how the brain processes itch, that might occur uniquely for chronic itch populations, could be used to guide more effective psychotherapeutic interventions for these groups. To build the evidence base for such approaches, we conducted a series of coordinates-based fMRI analyses, to identify the shared neural mechanisms for itch across the published literature. Upon so doing, we identified a core "itch network" that spans the Basal Ganglia/Thalamus, Claustrum and Insula. Additionally, we found evidence that the Paracentral Lobule and Medial Frontal Gyrus, regions associated with cognitive control and response inhibition, deactivate during itch. Interestingly, a separate analysis for chronic itch populations identified significant recruitment of the Left Paracentral Lobule, potentially suggesting the recruitment of cognitive control mechanisms to resist the urge to scratch. We position these results in light of further integrative studies that could use neuroimaging alongside clinical studies, to explore how transdiagnostic psychological approaches-such as mindfulness and compassion training-might help to improve quality of life for individuals who experience chronic itch.
Adverse reactions associated with theophylline are generally mild when serum theophylline concentrations are less than 20 mcg/mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When serum theophylline concentrations exceed 20 mcg/mL, however, theophylline produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal (see OVERDOSAGE).

Other adverse reactions that have been reported at serum theophylline concentrations less than 20 mcg/mL include diarrhea, irritability, restlessness, fine skeletal muscle tremors, and transient diuresis. In patients with hypoxia secondary to COPD, multifocal atrial tachycardia and flutter have been reported at serum theophylline concentrations greater than or equal to 15 mcg/mL. There have been a few isolated reports of seizures at serum theophylline concentrations less than 20 mcg/mL in patients with an underlying neurological disease or in elderly patients. The occurrence of seizures in elderly patients with serum theophylline concentrations less than 20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. The clinical characteristics of the seizures reported in patients with serum theophylline concentrations less than 20 mcg/mL have generally been milder than seizures associated with excessive serum theophylline concentrations resulting from an overdose (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua). There have been reports of non-convulsive status epilepticus in patients receiving theophylline, and this possibility should be considered in patients with abnormal central nervous system function and a history of theophylline administration. Hypercalcemia has been reported in a patient with hyperthyroid disease at therapeutic theophylline concentrations (see OVERDOSAGE).

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
All patients will be evaluated preoperatively in the anesthesia outpatient clinic, their consent will be obtained, and they will be informed about the 'Postoperative Recovery Evaluation' and pre-tests will be performed. All patients will receive premedication midazolam 0.07mg/kg intramuscularly 20 minutes before the operation. In both groups, anesthesia induction will be achieved with intravenous propofol 3 mg/kg, remifentanil 0.1 mic/kg, and rocuronium 0.06 mg/kg. Following endotracheal intubation, maintenance of anesthesia will be provided to the patients in Group I by inhalation, with sevoflurane MAC 1 in O2/Air 1/3 (4lt/min). On the other hand, patients in Group II will be switched to O2/Air 0.16/0.48 (0.5 lt/min) low flow anesthesia 15 minutes after the depth of anesthesia is provided (BIS\<50) and inhalation anesthesia starts. Remifentanil infusion will be administered intravenously at 0.025-0.1 mic/kg/min to all patients in both groups for peroperative analgesia. For postoperative analgesia, fentanyl will be administered intravenously as 2 mic/kg 10 minutes before the end of the surgery. In group I patients, remifentanil infusion and inhalation anesthesia will be reduced and stopped at the end of surgery. (BIS maximum 60). In patients in Group II, inhalation anesthesia will be terminated 15 minutes before the end of surgery, and remifentanil infusion will be terminated with the last suture. (BIS maximum 60). Peroperatively, patients' heart rate, mean blood pressure, oxygen saturation with pulse oximetry, tidal volume, respiratory rate, inspiratory/expiratory oxygen/air/sevoflurane concentrations, leakage amounts, end tidal CO2 and inspiratory CO2 amounts, BIS values will be recorded at 15-minute intervals. . The end of the surgery, the last suture of the surgery, the end of the anesthesia will be recorded as the termination of the administration of intravenous and inhalation anesthetics. Muscle laxity of the patients will be restored with sugammadex 2 mg/kg. As the extubation criteria, the spontaneous ventilation of the patients with sufficient tidal volume and the end of muscle relaxation will be taken as BIS \>70. The extubation time will be recorded. Postoperative recovery evaluations of the patients will be made. Nausea/vomiting and Modified Aldrete scores and VAS values of the patients followed for 30 minutes in the recovery unit will be recorded. At the end of the first 30 minutes, PQRS Cognitive test will be applied to the patients. On the morning of the first postoperative day, the QoR40 test will be applied and scored by an anesthesia technician who does not know the anesthesia method. The results will be compared.
After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
The study aimed to analyze the effects of Dendrobium polysaccharides on the cough and airway reactivity and compare them with the effects of clinically used antitussives (codeine phosphate and butamirate citrate) and bronchodilators (salbutamol), using the guinea pig test system. Dendrobium officinale polysaccharides contained proteins (4.0 wt%) and phenolic compounds (1.7 wt%) with a molecular weight of 25,000 g/mol. The sugar analysis revealed a dominance of glucose (93.7 wt%) and a lesser amount of mannose (5.1 wt%) while other sugar quantities were negligible. Methylation analysis indicated the presence of highly branched polysaccharides. Glucose was found mainly as terminal, 1,4- and 1,6-linked. Furthermore, some 1,4- and 1,6-linked glucose units were found branched at O2, O3, and O6/O4. Mannose was terminal and 1,4-linked. NMR spectra signals indicate the presence of the (1→4)-linked α-d-glucan, (1→4)-linked β-d-glucan branched at position O6, (1→6)-linked β-d-glucan branched at position O3 and (1→4)-linked glucomannan. Pharmacological studies showed statistically significant antitussive activity of Dendrobium polysaccharides, exceeding the effect of clinically used antitussives, which may be partially associated with confirmed bronchodilation and the ability of polysaccharides to increase the threshold of cough receptor activation. Dendrobium polysaccharides may increase the possibility of symptomatic treatment of cough, especially in asthmatics.